source
- Experts debate extra regulation for low-risk digital wellness devicesTwo recent papers published in JAMA have highlighted concerns about low-risk digital health technologies that consumers use. Experts say that even though these tools are considered low-risk, they…
- Novo vs. Lilly: Q2's cardiometabolic grudge matchFor years, Novo Nordisk and Eli Lilly have dominated the conversation surrounding obesity medicines as the duopoly competes to lead the largest pharmaceutical category in history. While dozens of c…